Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 (CN201) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT06189391Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2021
- Primary completion
- Sep 2028
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CN201 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicity at 28 days, Adverse Events at 15 months and 2 more. Started Mar 2021; status: recruiting.
02
Drugs
CN201
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06189391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189391.